New 48-week data from the Phase IIIb APEX trial (NCT04882098) show Tremfya (guselkumab; Johnson & Johnson) produces sustained inhibition of radiographic progression and improved clinical symptoms in ...
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback